Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Pork Tapeworm Infection Treatment Market Snapshot (2023 to 2033)

The global pork tapeworm infection treatment market is expected to reach US$ 11.66 Billion in 2023 and is projected to exhibit a CAGR of 8% from 2023 to 2033. As tapeworms become more prevalent, oral medications to treat them are becoming more popular. Despite its prevalence in poor rural countries around the world, Taenia solium continues to pose a serious public health threat. The parasite Neurocysticercosis (NCC) causes severe neurological infections in endemic regions, causing up to one-third of seizure disorders.

In partnership with Bayer AG, the World Health Organization renewed its collaboration which expanded assistance to millions of people suffering from neglected tropical diseases (NTD). There were also medicines from Bayer donated to support the control of cysticercosis and taeniasis.

Tapeworm infestations are being researched, but no new treatments have been approved for pork tapeworms. Plant-based compounds are being explored as a technique for preventing tapeworms from absorbing nutrients, and viruses engineered with genetic material are being investigated for killing tapeworm eggs. In addition, probiotics are being explored as a way to combat parasites. In the future, new treatments are expected to become available, but pork tapeworm medications are not yet approved.

It is imperative that the world's leading producers of pork tapeworm infection treatment expand their production facilities and retaining competitiveness in the pork tapeworm infection treatment market requires establishing long-term distribution agreements with large local distribution firms. A number of tests are being undertaken by companies in order to ensure the accuracy of the results in the market.

Data Points Key Statistics
Estimated Base Year Value (2022) US$ 11 Billion
Expected Market Value (2023) US$ 11.66 Billion
Anticipated Forecast Value (2033) US$ 25.17 Billion
Projected Growth Rate (2023 to 2033) 8% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Pork Tapeworm Infection Treatment Demand Analysis vs. Forecast 2023 to 2033

According to a report from Future Market Insights (FMI), from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%. As health awareness rises, and there is a high incidence of foodborne diseases such as tapeworm infection, the pork tapeworm infection treatment market is expected to grow rapidly.

Approximately 50 million people suffer from epilepsy worldwide, and more than 80 percent live in developing countries. The most effective way to control and break the life cycle of the parasite requires detailed case findings, better diagnosis and treatment, and public health information campaigns. With the aim of reducing the burden of PPBDs among ethnic minority communities in Vietnam, the Safer Indigenous Pork and Healthy Minorities project from January 2018 to June 2020 was developed.

Researchers studying the treatment of pork tapeworm infections have the potential to develop new treatments, treatment strategies, and diagnostic tools that can support the fight against this infection. A new diagnostic technique or drug, a vaccine, or some preventative measure might be among them. There may also be new avenues for treatment to be explored as researchers continue to investigate the biology and genetic makeup of the parasite. Further studies undertaken into the epidemiology of this disease may also help provide insights into the way in which it can be controlled and prevent its spread in the future.

There is a strong likelihood that the increased awareness about sanitizing hands and being able to cook food thoroughly in the future will further drive the market demand for pork tapeworm infection treatment. The global demand for pork tapeworm infection treatment is projected to increase at a CAGR of 11% during the forecast period between 2023 and 2033, reaching a total of US$ 25.17 Billion in 2033.

Why is the Pork Tapeworm Infection Treatment Market Growing?

Governmental Awareness Programs will enhance the Growth of the Market

Foods derived from animals are becoming increasingly concerned about food safety, especially those that are required to meet people's nutritional needs, especially women and children. Due to low awareness of infection risks and higher unhygienic places in urban and rural areas, the market is predicted to grow. Over the forecast period, the market is expected to grow due to the increasing incidence of tapeworms, as well as high investment in tapeworm treatment research. Several government-sponsored awareness campaigns regarding cattle and pork infections have pushed market demand for the treatments due to increased research and development funding.

As part of this program, efforts are being coordinated between the Ministry of Women and Child Development, the Department of School Education and Literacy of the Ministry of Human Resources and Development, and the Ministry of Drinking Water and Sanitation. As part of deworming program support, the Ministry of Panchayati Raj, Ministry of Tribal Affairs, Ministry of Rural Development, Ministry of Urban Development, and Urban Local Bodies (ULBs) have also stepped forward.

New Vaccines and Drugs will drive Market Growth in the Future

Researchers are developing new vaccines and medications to treat pork tapeworms. With the invention of drug therapies that target the parasite's life cycle, as well as vaccines to prevent the infection from occurring at all, new drugs can be made available to help reduce the global burden of disease caused by pork tapeworms. Pork tapeworms cause a large number of diseases globally. These tools could make a big difference. It is anticipated that one or more pharmaceutical companies will invest in the development of new drugs intended to target pork tapeworms specifically.

In addition to developing an anthelmintic strategy targeting the tapeworm adult, research is underway to develop anthelmintic cocktails targeting the tapeworm at multiple stages of its life cycle. Further studies are also underway to develop vaccines that could potentially reduce the risk of pork tapeworm infection through the development of vaccines. It is most common to contract the parasite at the larval stage, so these vaccines are targeting this stage of infection. Infection with pork tapeworms can be treated better and more effectively with the help of all these efforts.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Factors Restraining Pork Tapeworm Infection Treatment Demand?

Lack of awareness and Timely Treatment will limit the expansion

Approximately half of all pig tapeworm infections are not diagnosed and are not treated because of the delay in diagnosing them, hence the market is expected to hamper. In addition, limited drug development combined with a high cost for the diagnosis is expected to make the growth of the market difficult.

Nevertheless, higher research and development costs as well as high adverse reaction rates caused due to the inflammatory reaction of the body are key factors limiting global pork tapeworm infection treatment demand.

Country-Wise Insights                                    

What Effect will North America Have on Pork Tapeworm Infection Treatment?

Governmental Guidelines to Surge the Market Demand for Drugs and Treatments

North America is estimated to account for the second-largest segment of the global pork tapeworm infection treatment market during the forecast period. A government guideline was published regarding the treatment of these infections, as well as the use of albendazole.

For instance, AAN (American Academy of Neurology) released a set of evidence-based guidelines that are intended to treat neurocysticercosis, a tapeworm infection that causes seizures, and is on the rise in developed countries. Neurocysticercosis is also considered a health threat in the United States. American Academy of Neurology's medical journal Neurology published the guideline on April 9, 2013. A combination of albendazole and a corticosteroid was found to be effective in treating neurocysticercosis following a review of all available evidence. In order to get rid of the parasite, albendazole was taken as a medication.

What has Been the Impact of Pork Tapeworm Infection Treatment on the European Market?

As Economic Conditions Change and Cattle Restocking Increases, Pork Tapeworm Infections are on the Rise

According to forecasts, Europe will hold the largest market for pork tapeworm infection treatment. In this region, pork tapeworm infection treatments account for 28% of the total market. Europe's success has been largely attributed to its high diagnosis rates, modern medical facilities, and increased research and development efforts. Taenia solium exists as an endemic species throughout the world. As a result of industrialization and improved sanitation, this parasite is believed to have been eradicated from Europe's pig-rearing systems.

Increasing cattle rearing practices and raw meat consumption have prone consumers to tapeworm infections, so the market for advanced treatments is expected to grow. It is anticipated that a greater awareness program about infections and education in this area will also contribute to the growth of the market in the future. As economic conditions improve and spending habits increase, the pork tapeworm infection treatment market is expected to grow.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

What is the Growth Potential of the Albendazole Market?

Increased Awareness About Veterinary Care is Driving Market Growth

The market for the albendazole drug type is expected to grow at a CAGR of 6.2% from 2023 to 2033. As albendazole is FDA-approved for treating various parasitic worm infections, the market for these drugs is expected to grow. Increasing demand for these drugs is expected to fuel growth in the market for treating various infections in humans and animals.

Roundworms, tapeworms, hookworms, and other helminths are projected to increase in prevalence, causing an increase in the demand for antihelmintic drugs in the market. The number of albendazole drugs sold in developing countries is substantial since these regions are often the victims of tapeworm infections, which often cause them to buy albendazole drugs. There is also a possibility that the modernization of the healthcare industry will increase the number of opportunities on the market in the near future. Further, researchers are developing novel formulations of albendazole with the aim of optimizing the drug's therapeutic effectiveness by transferring the drug into micro-emulsifying delivery systems and increasing the lipid-solubility of the dosage form.

How Diagnostic Tools are Helps Treat Pork Tapeworms?

Demand for Advanced Diagnostic Tools to Treat Pork Tapeworm Infection will Increase

Based on the treatment, the global market is segmented into CT scans, MRI, Ultrasound, and X-rays. Revenues from CT scans are forecast to grow by 22% during the forecast period. X-rays, CT scans, MRI scans, or ultrasounds can be used to detect invasive tapeworm infections. Advances in technology and advanced machines to detect illness are driving the growth of these tools in the market.

Most people with cysticercosis do not have positive stool tests for pork tapeworms, according to the Merck Manual. In the case of individuals that exhibit symptoms of an infection in their nervous system, two imaging tests are often used to diagnose cysticercosis or neurocysticercosis: computed tomography (CT) scans and magnetic resonance imaging (MRI). Due to the increased availability and affordability of these tests, especially in developing regions, the market for these tests for pork tapeworm infection treatment is expected to grow.

The Start-up Ecosystem: How are Start-ups Securing Future Growth Opportunities?

Some of the start-ups in the pork tapeworm infection treatment market include-

  • Pathogen DX, which detects porcine tapeworms and other parasites and pathogens using molecular diagnostic tests. In pork products, its technology detects and identifies porcine tapeworms and other parasites.
  • BioNano Genomics: Porcine tapeworm identification is now made simpler by BioNano Genomics. With the company's next-generation sequencing technology, porcine tapeworm populations in pork products are accurately identified, characterized, and quantified.
  • Genalysis: Detection of porcine tapeworms in pork products is performed with a rapid, one-step PCR assay. Pork products are also treated against porcine tapeworm infections by using a variety of solutions provided by the company.

Market Competition

By increasing production and meeting consumer demands, strategic partnerships can help manufacturers boost revenue and market share. Promote new products and technologies to end users so they can benefit from their use. A partnership can increase a company's production capacity by forming a strategic partnership.

  • An anti-pathogen armamentarium is being built by Mukesh Ambani's conglomerate, Reliance Industries Ltd., which is working on a new drug for COVID-19, as well as cheaper testing kits. Several drugs, including Niclosamide, are being investigated as possible treatments for Covid-19, according to the company's annual report. A process has been designed to make sanitizers at one-fifth the market cost using R-Green and R-Green Pro diagnostic kits, which were approved by the Indian national medical research body, and they are aiming to sell the kits in India within three years.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 11.66 Billion
Market Value in 2033 US$ 25.17 Billion
Growth Rate CAGR 8%
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Type
  • Treatment
  • End User
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • The USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • Winchester Hospital
  • Merck & Company Inc.
  • Medtronic
  • Teva Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Sanofi S.A.
  • Bayer AG
  • Bristol-Myers Squibb
  • Abbott
  • Recordati Rare Diseases Inc.
Customization Available Upon Request

Key Segments Profiled in the Pork Tapeworm Infection Treatment Market Industry Survey

By Drug Type:

  • Praziquantel
  • Albendazole
  • Nitazoxanide
  • Others

By Treatment:

  • CT Scan
  • MRI
  • Ultrasound
  • X-Ray

By End User:

  • Hospitals & Laboratories
  • Specialty Clinics
  • Ambulatory Surgical Centres
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

How big is the Pork Tapeworm Infection Treatment Market?

The market is valued at US$ 11.66 Billion in 2023.

Who are the key market players?

Winchester Hospital, Merck & Company Inc. and Medtronic are key market players.

Which is the key segment by drug type?

Albendazole drug market to grow 6.2% CAGR (2023-2033).

How was the market’s historical performance?

From 2018 to 2022, the market registered a 5.2% CAGR.

What is Europe’s market share?

Europe will hold a 28% share in 2023.

Table of Content

1. Executive Summary | Pork Tapeworm Infection Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Praziquantel

        5.3.2. Albendazole

        5.3.3. Nitazoxanide

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ million) Analysis By Treatment, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Treatment, 2023 to 2033

        6.3.1. CT scan

        6.3.2. MRI

        6.3.3. Ultrasound

        6.3.4. X-ray

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ million) Analysis By End-Users, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End-Users, 2023 to 2033

        7.3.1. Hospitals & Laboratories

        7.3.2. Specialty Clinics

        7.3.3. Ambulatory Surgical Centres

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. The USA

            10.2.1.2. Canada

        10.2.2. By Drug Type

        10.2.3. By Treatment

        10.2.4. By End-Users

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Treatment

        10.3.4. By End-Users

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Type

        11.2.3. By Treatment

        11.2.4. By End-Users

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Treatment

        11.3.4. By End-Users

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. The United Kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Drug Type

        12.2.3. By Treatment

        12.2.4. By End-Users

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Treatment

        12.3.4. By End-Users

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Drug Type

        13.2.3. By Treatment

        13.2.4. By End-Users

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Treatment

        13.3.4. By End-Users

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Type

        14.2.3. By Treatment

        14.2.4. By End-Users

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Treatment

        14.3.4. By End-Users

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Drug Type

        15.2.3. By Treatment

        15.2.4. By End-Users

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Treatment

        15.3.4. By End-Users

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Type

        16.2.3. By Treatment

        16.2.4. By End-Users

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Type

        16.3.3. By Treatment

        16.3.4. By End-Users

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. The USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Type

            17.1.2.2. By Treatment

            17.1.2.3. By End-Users

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Type

            17.2.2.2. By Treatment

            17.2.2.3. By End-Users

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Type

            17.3.2.2. By Treatment

            17.3.2.3. By End-Users

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Type

            17.4.2.2. By Treatment

            17.4.2.3. By End-Users

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Type

            17.5.2.2. By Treatment

            17.5.2.3. By End-Users

            17.5.2.4. By Distribution Channel

    17.6. The United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Type

            17.6.2.2. By Treatment

            17.6.2.3. By End-Users

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Type

            17.7.2.2. By Treatment

            17.7.2.3. By End-Users

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Type

            17.8.2.2. By Treatment

            17.8.2.3. By End-Users

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Type

            17.9.2.2. By Treatment

            17.9.2.3. By End-Users

            17.9.2.4. By Distribution Channel

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Type

            17.10.2.2. By Treatment

            17.10.2.3. By End-Users

            17.10.2.4. By Distribution Channel

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Type

            17.11.2.2. By Treatment

            17.11.2.3. By End-Users

            17.11.2.4. By Distribution Channel

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Type

            17.12.2.2. By Treatment

            17.12.2.3. By End-Users

            17.12.2.4. By Distribution Channel

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Type

            17.13.2.2. By Treatment

            17.13.2.3. By End-Users

            17.13.2.4. By Distribution Channel

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Type

            17.14.2.2. By Treatment

            17.14.2.3. By End-Users

            17.14.2.4. By Distribution Channel

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Type

            17.15.2.2. By Treatment

            17.15.2.3. By End-Users

            17.15.2.4. By Distribution Channel

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Type

            17.16.2.2. By Treatment

            17.16.2.3. By End-Users

            17.16.2.4. By Distribution Channel

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Type

            17.17.2.2. By Treatment

            17.17.2.3. By End-Users

            17.17.2.4. By Distribution Channel

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Type

            17.18.2.2. By Treatment

            17.18.2.3. By End-Users

            17.18.2.4. By Distribution Channel

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Type

            17.19.2.2. By Treatment

            17.19.2.3. By End-Users

            17.19.2.4. By Distribution Channel

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Type

            17.20.2.2. By Treatment

            17.20.2.3. By End-Users

            17.20.2.4. By Distribution Channel

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Type

            17.21.2.2. By Treatment

            17.21.2.3. By End-Users

            17.21.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Type

        18.3.3. By Treatment

        18.3.4. By End-Users

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Winchester Hospital

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Merck & Company Inc.

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Medtronic

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Teva Pharmaceuticals Ltd.

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Eli Lilly and Company

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Sanofi S.A.

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Bayer AG

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Bristol-Myers Squibb.

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Abbott

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Recordati Rare Diseases Inc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 3: Global Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 4: Global Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 5: Global Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 6: North America Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 7: North America Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 8: North America Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 9: North America Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 10: North America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 11: Latin America Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 12: Latin America Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 13: Latin America Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 14: Latin America Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 15: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 16: Europe Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 17: Europe Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 18: Europe Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 19: Europe Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 20: Europe Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 21: South Asia Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 22: South Asia Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 23: South Asia Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 24: South Asia Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 25: South Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 26: East Asia Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 27: East Asia Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 28: East Asia Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 29: East Asia Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 30: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 31: Oceania Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 32: Oceania Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 33: Oceania Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 34: Oceania Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 35: Oceania Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033

Table 36: MEA Market Value (US$ million) Forecast by Country, 2018 to 2033

Table 37: MEA Market Value (US$ million) Forecast by Drug Type, 2018 to 2033

Table 38: MEA Market Value (US$ million) Forecast by Treatment, 2018 to 2033

Table 39: MEA Market Value (US$ million) Forecast by End-Users, 2018 to 2033

Table 40: MEA Market Value (US$ million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 2: Global Market Value (US$ million) by Treatment, 2023 to 2033

Figure 3: Global Market Value (US$ million) by End-Users, 2023 to 2033

Figure 4: Global Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 5: Global Market Value (US$ million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ million) Analysis by Region, 2018 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 12: Global Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 15: Global Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 18: Global Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 21: Global Market Attractiveness by Drug Type, 2023 to 2033

Figure 22: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 23: Global Market Attractiveness by End-Users, 2023 to 2033

Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 25: Global Market Attractiveness by Region, 2023 to 2033

Figure 26: North America Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 27: North America Market Value (US$ million) by Treatment, 2023 to 2033

Figure 28: North America Market Value (US$ million) by End-Users, 2023 to 2033

Figure 29: North America Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 30: North America Market Value (US$ million) by Country, 2023 to 2033

Figure 31: North America Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 37: North America Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: North America Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 43: North America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 46: North America Market Attractiveness by Drug Type, 2023 to 2033

Figure 47: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 48: North America Market Attractiveness by End-Users, 2023 to 2033

Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 50: North America Market Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 52: Latin America Market Value (US$ million) by Treatment, 2023 to 2033

Figure 53: Latin America Market Value (US$ million) by End-Users, 2023 to 2033

Figure 54: Latin America Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 55: Latin America Market Value (US$ million) by Country, 2023 to 2033

Figure 56: Latin America Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 62: Latin America Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 65: Latin America Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 68: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 71: Latin America Market Attractiveness by Drug Type, 2023 to 2033

Figure 72: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 73: Latin America Market Attractiveness by End-Users, 2023 to 2033

Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 76: Europe Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 77: Europe Market Value (US$ million) by Treatment, 2023 to 2033

Figure 78: Europe Market Value (US$ million) by End-Users, 2023 to 2033

Figure 79: Europe Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 80: Europe Market Value (US$ million) by Country, 2023 to 2033

Figure 81: Europe Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Europe Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 85: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 86: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 87: Europe Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 88: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 89: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 90: Europe Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 91: Europe Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 92: Europe Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 93: Europe Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 96: Europe Market Attractiveness by Drug Type, 2023 to 2033

Figure 97: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 98: Europe Market Attractiveness by End-Users, 2023 to 2033

Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: South Asia Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 102: South Asia Market Value (US$ million) by Treatment, 2023 to 2033

Figure 103: South Asia Market Value (US$ million) by End-Users, 2023 to 2033

Figure 104: South Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 105: South Asia Market Value (US$ million) by Country, 2023 to 2033

Figure 106: South Asia Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: South Asia Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 110: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 112: South Asia Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 113: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 115: South Asia Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 116: South Asia Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 117: South Asia Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 118: South Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 121: South Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 122: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 123: South Asia Market Attractiveness by End-Users, 2023 to 2033

Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 126: East Asia Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 127: East Asia Market Value (US$ million) by Treatment, 2023 to 2033

Figure 128: East Asia Market Value (US$ million) by End-Users, 2023 to 2033

Figure 129: East Asia Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 130: East Asia Market Value (US$ million) by Country, 2023 to 2033

Figure 131: East Asia Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: East Asia Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 135: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 137: East Asia Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 138: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 140: East Asia Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 141: East Asia Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 142: East Asia Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 143: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 146: East Asia Market Attractiveness by Drug Type, 2023 to 2033

Figure 147: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 148: East Asia Market Attractiveness by End-Users, 2023 to 2033

Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 151: Oceania Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 152: Oceania Market Value (US$ million) by Treatment, 2023 to 2033

Figure 153: Oceania Market Value (US$ million) by End-Users, 2023 to 2033

Figure 154: Oceania Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 155: Oceania Market Value (US$ million) by Country, 2023 to 2033

Figure 156: Oceania Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 159: Oceania Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 160: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 162: Oceania Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 163: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 165: Oceania Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 166: Oceania Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 167: Oceania Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 168: Oceania Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 171: Oceania Market Attractiveness by Drug Type, 2023 to 2033

Figure 172: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 173: Oceania Market Attractiveness by End-Users, 2023 to 2033

Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 176: MEA Market Value (US$ million) by Drug Type, 2023 to 2033

Figure 177: MEA Market Value (US$ million) by Treatment, 2023 to 2033

Figure 178: MEA Market Value (US$ million) by End-Users, 2023 to 2033

Figure 179: MEA Market Value (US$ million) by Distribution Channel, 2023 to 2033

Figure 180: MEA Market Value (US$ million) by Country, 2023 to 2033

Figure 181: MEA Market Value (US$ million) Analysis by Country, 2018 to 2033

Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 184: MEA Market Value (US$ million) Analysis by Drug Type, 2018 to 2033

Figure 185: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033

Figure 186: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033

Figure 187: MEA Market Value (US$ million) Analysis by Treatment, 2018 to 2033

Figure 188: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 189: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 190: MEA Market Value (US$ million) Analysis by End-Users, 2018 to 2033

Figure 191: MEA Market Value Share (%) and BPS Analysis by End-Users, 2023 to 2033

Figure 192: MEA Market Y-o-Y Growth (%) Projections by End-Users, 2023 to 2033

Figure 193: MEA Market Value (US$ million) Analysis by Distribution Channel, 2018 to 2033

Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 196: MEA Market Attractiveness by Drug Type, 2023 to 2033

Figure 197: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 198: MEA Market Attractiveness by End-Users, 2023 to 2033

Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 200: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Infection Prevention Market

Published : December 2023

Healthcare

Fungal Keratitis Treatment Market

Published : August 2023

Healthcare

Infectious Disease Diagnostics Market

Published : November 2022

Explore Healthcare Insights

View Reports

Pork Tapeworm Infection Treatment Market